ArticleAntimicrobial agents and chemotherapy2019
Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Nanoemulsion-based colistin for pulmonary delivery: Enhanced antibacterial efficacy against Acinetobacter baumannii.Drug delivery and translational research · 2026Article
- Zwitterionic Penicillin-Derived Sulfone Inhibitor for Combating β-Lactamase-Mediated Antibiotic Resistance.ChemMedChem · 2026Article
- Carbapenem Resistance inMicroorganisms · 2025Review
- Article
- β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics.Chemical reviews · 2021Review
- Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 againstAntibiotics (Basel, Switzerland) · 2021Article
- New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Juan Carlos Vázquez-Ucha *Servicio de Microbiología do Complexo Hospitalario Universitario da Coruña (CHUAC), Instituto de Investigación Biomédica da Coruña (INIBIC)-Centro de Investigacións Científicas Avanzadas (CICA), A Coruña, Spain.
Marta Martínez-Guitián *Servicio de Microbiología do Complexo Hospitalario Universitario da Coruña (CHUAC), Instituto de Investigación Biomédica da Coruña (INIBIC)-Centro de Investigacións Científicas Avanzadas (CICA), A Coruña, Spain.
María Maneiro *Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Kelly Conde-PérezServicio de Microbiología do Complexo Hospitalario Universitario da Coruña (CHUAC), Instituto de Investigación Biomédica da Coruña (INIBIC)-Centro de Investigacións Científicas Avanzadas (CICA), A Coruña, Spain.
Laura Álvarez-FragaServicio de Microbiología do Complexo Hospitalario Universitario da Coruña (CHUAC), Instituto de Investigación Biomédica da Coruña (INIBIC)-Centro de Investigacións Científicas Avanzadas (CICA), A Coruña, Spain.
Gabriel TorrensServicio de Microbiología y Unidad de Investigación, Hospital Universitari Son Espases, Institut d'Investigació Sanitaria Illes Balears, Palma de Mallorca, Spain.
Antonio OliverServicio de Microbiología y Unidad de Investigación, Hospital Universitari Son Espases, Institut d'Investigació Sanitaria Illes Balears, Palma de Mallorca, Spain.ORCID 0000-0001-9327-1894
John D BuynakDepartment of Chemistry, Southern Methodist University, Dallas, Texas, USA.
Robert A BonomoMedical Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Germán BouServicio de Microbiología do Complexo Hospitalario Universitario da Coruña (CHUAC), Instituto de Investigación Biomédica da Coruña (INIBIC)-Centro de Investigacións Científicas Avanzadas (CICA), A Coruña, Spain.
Concepción González-Bello *Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Margarita Poza *Servicio de Microbiología do Complexo Hospitalario Universitario da Coruña (CHUAC), Instituto de Investigación Biomédica da Coruña (INIBIC)-Centro de Investigacións Científicas Avanzadas (CICA), A Coruña, Spain.
Alejandro Beceiro *Servicio de Microbiología do Complexo Hospitalario Universitario da Coruña (CHUAC), Instituto de Investigación Biomédica da Coruña (INIBIC)-Centro de Investigacións Científicas Avanzadas (CICA), A Coruña, Spain Alejandro.Beceiro.Casas@sergas.es.
Complexo Hospitalario Universitario A Coruña · ESHealth Research Institute of the Balearic Islands · ESUniversidade de Santiago de Compostela · ESLouis Stokes Cleveland VA Medical Center · USSouthern Methodist University · US
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MAntibiotics Designed to Counter Resistant 21st Century PathogensR15AI142699 · NIAID · SOUTHERN METHODIST UNIVERSITY · PI BUYNAK, JOHN D · 2019 to 2019
$437kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R15 AI142699
Abstract
The carbapenem-hydrolyzing class D β-lactamases (CHDLs) are the main mechanism of carbapenem resistance in
Indexed as
Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Infective AgentsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasesCyclic S-OxidesDrug Resistance, Multiple, BacterialImipenemMaleMiceMice, Inbred BALB CMicrobial Sensitivity TestsPenicillinsAnti-Infective AgentsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasescarbapenemaseCyclic S-OxidesImipenemLN 1-255PenicillinsAcinetobacter baumanniianimal modelsantimicrobial agentsbeta-lactamase inhibitorclass D carbapenemasespreclinical drug studies
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.